MAPT and early-onset autosomal dominant Alzheimer disease: Together, they mitigate CDK5-induced neurodegeneration by regulating Tau hyperphosphorylation, oxidative stress, and neuronal apoptosis, making FAM110B and YWHAE potential therapeutic targets in Alzheimer’s disease.